Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

ADA Spotlight: Novo Nordisk, Boehringer Ingelheim, Eli Lilly and More

Almost 15,000 physicians, scientists, health-care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association (ADA)’s 79th Scientific Sessions in San Francisco.

Read More »

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.

Read More »

Vitamin D fails to prevent type 2 diabetes in large study

A new study found that taking 4,000 international units per day may double the amount of vitamin D in the blood, but it gives most people roughly the same chance of developing blood sugar problems as people who do not take the vitamin.

Read More »

Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart

Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

New diabetes guidelines imminent, Jardiance sales may surge

Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom